M&A / Deals Alzheimer’s biotech Korsana to go public via reverse merger PharmaphorumBy merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.M&A / DealsNeuroscienceRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaphorum By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer’s. M&A / DealsNeuroscienceRead full story Post navigation Previous: Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assetsNext: Merck KGaA acquires JSR chromatography business Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026